Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Nephrology

Survivorship and Planning for the Future

At a Glance

Managing Alport syndrome is a lifelong process that requires regular monitoring of kidney function, hearing, and vision. Proactive care, emotional support, and genetic counseling for family planning can help patients live well and make highly informed choices for their future families.

Living with Alport syndrome is a marathon, not a sprint. Because it is a lifelong condition, management shifts from the initial “emergency” of diagnosis to a steady rhythm of monitoring, self-care, and looking toward the future. By staying proactive, you can manage the physical symptoms while protecting your emotional well-being and making informed choices for your family.

A Lifetime of Vigilance: The Monitoring Schedule

Regular surveillance is the best tool for protecting kidney function. While your specific schedule depends on your genotype and symptoms, the general “cadence” of care often includes:

  • Kidney Function (Every 3–12 months): Your team will monitor your blood pressure and use two vital tests to evaluate your kidneys: eGFR (estimated Glomerular Filtration Rate, which measures how well the kidneys are filtering waste) and uACR (Urine Albumin-to-Creatinine Ratio, which checks for the amount of protein leaking into your urine) [1][2]. If uACR levels increase, your doctor may adjust your medication [3].
  • Hearing (Every 1–2 years): Because high-frequency hearing loss can be subtle, regular audiograms (hearing tests) are essential, especially during childhood and adolescence [4][5].
  • Vision (Every 1–2 years): A dilated eye exam with an ophthalmologist can monitor for anterior lenticonus or retinal changes [6][7]. These screenings are vital barometers for the overall state of the disease [5].

The Emotional Landscape

Managing a chronic, progressive condition takes a significant mental toll. It is common to experience “scan anxiety”—the stress that builds up before a doctor’s visit or lab result [8][9].

  • Acknowledge the Burden: Chronic kidney disease can impact your quality of life, leading to feelings of anxiety, depression, or isolation [10][11].
  • Holistic Support: Modern care should include more than just blood tests. Integrating mental health support and connecting with advocacy groups can help you navigate the “worry” about the future and focus on living well today [8][12].

Looking Ahead: Family Planning

Because Alport syndrome is hereditary, many patients and families have questions about passing the condition to the next generation. You have more options today than ever before.

The Role of Genetic Counseling

A genetic counselor can help you understand the specific inheritance pattern in your family (XLAS, ARAS, or ADAS) and what that means for your children [13][14]. They are essential partners in navigating reproductive choices [15].

Reproductive Options

  • PGT-M (Pre-implantation Genetic Testing): For families using IVF, this technology allows embryos to be tested for the specific Alport mutation before they are transferred to the uterus. This can prevent the intergenerational transmission of the disease [16][17].
  • Prenatal Testing: Options such as amniocentesis or chorionic villus sampling (CVS) can identify if a fetus has the family mutation during pregnancy [18][14].
  • Cascade Screening: If you have been diagnosed, your relatives should also be offered testing. Identifying “hidden” cases in the family early can ensure everyone gets the kidney-protective care they need [19][20].

Management of Alport syndrome is no longer just about waiting for things to change. It is about active surveillance, emotional resilience, and using modern science to build the future you want [21][22].

Common questions in this guide

How often should my kidney function be checked with Alport syndrome?
Your kidney function should typically be monitored every 3 to 12 months. This routine check includes measuring your blood pressure, estimated Glomerular Filtration Rate (eGFR), and Urine Albumin-to-Creatinine Ratio (uACR) to track how well your kidneys filter waste.
Do I need regular hearing and eye exams if I have Alport syndrome?
Yes. Because Alport syndrome can cause high-frequency hearing loss and eye issues like anterior lenticonus, you should have formal audiograms and dilated eye exams every 1 to 2 years. These screenings are vital barometers for the overall progression of the disease.
What reproductive options are available for families with Alport syndrome?
Families can use options like Pre-implantation Genetic Testing (PGT-M) during IVF to test embryos for the Alport mutation before pregnancy. Prenatal testing, such as amniocentesis or chorionic villus sampling (CVS), is also available to evaluate a fetus during pregnancy.
Should my relatives be tested for Alport syndrome if I am diagnosed?
Yes, cascade screening is highly recommended. Identifying the condition in family members early ensures they can begin kidney-protective care and regular monitoring before their symptoms become severe.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current urine protein and kidney function results, how frequently should we be scheduling lab work?
  2. 2.When should my child have their next formal audiogram and dilated eye exam?
  3. 3.Can you recommend a mental health professional who has experience with patients or families facing chronic, progressive diseases?
  4. 4.If we are considering having children, can you refer us to a genetic counselor who specializes in Alport syndrome and reproductive options?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Alport Syndrome: A Comprehensive Review.

    Adone A, Anjankar A

    Cureus 2023; (15(10)):e47129 doi:10.7759/cureus.47129.

    PMID: 38021591
  2. 2

    A Systematic Review of Pathogenic COL4A5 Variants and Proteinuria in Women and Girls With X-linked Alport Syndrome.

    Gibson JT, de Gooyer M, Huang M, Savige J

    Kidney international reports 2022; (7(11)):2454-2461 doi:10.1016/j.ekir.2022.08.021.

    PMID: 36531881
  3. 3

    Dysregulated Expression of microRNA-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome.

    Guo J, Song W, Boulanger J, et al.

    Human gene therapy 2019; (30(7)):865-881 doi:10.1089/hum.2018.205.

    PMID: 30808234
  4. 4

    Alport Syndrome: Achieving Early Diagnosis and Treatment.

    Kashtan CE

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (77(2)):272-279 doi:10.1053/j.ajkd.2020.03.026.

    PMID: 32712016
  5. 5

    Deciphering the pathogenesis of the COL4-related hematuric nephritis: A genotype/phenotype study.

    Uliana V, Sebastio P, Riva M, et al.

    Molecular genetics & genomic medicine 2021; (9(2)):e1576 doi:10.1002/mgg3.1576.

    PMID: 33369211
  6. 6

    Bilateral giant macular holes: A rare manifestation of Alport syndrome.

    Raimundo M, Fonseca C, Silva R, Figueira J

    European journal of ophthalmology 2019; (29(1)):NP13-NP16 doi:10.1177/1120672118781232.

    PMID: 29873249
  7. 7

    MACULAR HOLES, VITELLIFORM LESIONS, AND MIDPERIPHERAL RETINOSCHISIS IN ALPORT SYNDROME.

    Thomas AS, Baynham JT, Flaxel CJ

    Retinal cases & brief reports 2016; (10(2)):109-11 doi:10.1097/ICB.0000000000000176.

    PMID: 26200386
  8. 8

    Impact of COVID-19 on Health-Related Quality of Life and Mental Health Among Employees in Health and Social Services-A Longitudinal Study.

    Peters C, Dulon M, Schablon A, et al.

    Infectious disease reports 2025; (17(6)) doi:10.3390/idr17060138.

    PMID: 41283342
  9. 9

    Depression, anxiety, and health-related quality of life in normal weight, overweight and obese individuals with diabetes: a representative study in Germany.

    Herhaus B, Kruse J, Hinz A, et al.

    Acta diabetologica 2024; (61(6)):725-734 doi:10.1007/s00592-024-02248-7.

    PMID: 38430257
  10. 10

    Relation Among Anxiety, Depression, Sleep Quality and Health-Related Quality of Life Among Patients with Systemic Lupus Erythematosus: Path Analysis.

    Chen HJ, Wang H, Qiu LJ, et al.

    Patient preference and adherence 2022; (16()):1351-1358 doi:10.2147/PPA.S366083.

    PMID: 35642245
  11. 11

    Quality of life measures in Systemic Lupus Erythematosus: A systematic review.

    Radin M, El Hasbani G, Barinotti A, et al.

    Reumatismo 2022; (73(4)) doi:10.4081/reumatismo.2021.1447.

    PMID: 35130683
  12. 12

    Anxiety and depression in diabetes care: longitudinal associations with health-related quality of life.

    Liu X, Haagsma J, Sijbrands E, et al.

    Scientific reports 2020; (10(1)):8307 doi:10.1038/s41598-020-57647-x.

    PMID: 32433470
  13. 13

    Clinical, histological and molecular characteristics of Alport syndrome in Chinese children.

    Zhou L, Xi B, Xu Y, et al.

    Journal of nephrology 2023; (36(5)):1415-1423 doi:10.1007/s40620-023-01570-7.

    PMID: 37097554
  14. 14

    Prenatal and preimplantation genetic testing for monogenic kidney disorders.

    Knoers NVAM

    Kidney international 2025; (107(2)):255-261 doi:10.1016/j.kint.2024.06.031.

    PMID: 39477068
  15. 15

    Use of preimplantation genetic testing for monogenic defects (PGT-M) for adult-onset conditions: an Ethics Committee opinion.

    ,

    Fertility and sterility 2018; (109(6)):989-992 doi:10.1016/j.fertnstert.2018.04.003.

    PMID: 29935659
  16. 16

    Preimplantation genetic testing for monogenic disorders (PGT-M) for monogenic nephropathy: a single-center retrospective cohort analysis.

    Liu X, Zhang Q, Cao K, et al.

    Clinical kidney journal 2025; (18(1)):sfae356 doi:10.1093/ckj/sfae356.

    PMID: 39802589
  17. 17

    Preimplantation Genetic Testing Prevented Intergenerational Transmission of X-Linked Alport Syndrome.

    Hu X, Zhang J, Lv Y, et al.

    Kidney diseases (Basel, Switzerland) 2021; (7(6)):514-520 doi:10.1159/000517796.

    PMID: 34901197
  18. 18

    Prenatal genetic testing 2: diagnostic tests.

    Jenkins M, Seasely AR, Subramaniam A

    Current opinion in pediatrics 2022; (34(6)):553-558 doi:10.1097/MOP.0000000000001174.

    PMID: 36081360
  19. 19

    Carrier screening for Alport syndrome: The clinical importance of heterozygosity for pathogenic or likely pathogenetic variants.

    Souter V, Johnson L, Becraft E, et al.

    Journal of genetic counseling 2025; (34(3)):e70045 doi:10.1002/jgc4.70045.

    PMID: 40317772
  20. 20

    Guidelines for Genetic Testing and Management of Alport Syndrome.

    Savige J, Lipska-Zietkiewicz BS, Watson E, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2022; (17(1)):143-154 doi:10.2215/CJN.04230321.

    PMID: 34930753
  21. 21

    Multidisciplinary Management of Alport Syndrome: Current Perspectives.

    Kashtan C

    Journal of multidisciplinary healthcare 2021; (14()):1169-1180 doi:10.2147/JMDH.S284784.

    PMID: 34045864
  22. 22

    Public Awareness and Acceptability of PGT-M in Cancer Predisposition Syndromes.

    Calosci D, Passaglia L, Gabbiato I, et al.

    Genes 2023; (14(11)) doi:10.3390/genes14112069.

    PMID: 38003012

This page is for informational purposes only and does not replace professional medical advice regarding Alport syndrome monitoring or family planning. Always consult your healthcare team for specific guidance.

Get notified when new evidence is published on Alport syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.